The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPoolbeg Pharma Share News (POLB)

Share Price Information for Poolbeg Pharma (POLB)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 13.10
Bid: 12.90
Ask: 13.30
Change: -0.10 (-0.76%)
Spread: 0.40 (3.101%)
Open: 13.20
High: 13.20
Low: 13.05
Prev. Close: 13.20
POLB Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: CentralNic and Pebble tip 2021 earnings rise

Mon, 17th Jan 2022 17:04

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

----------

CentralNic Group PLC - London-based domain name registry and registrar services firm - Says organic growth "accelerated" in fourth quarter, which CentralNic attributes to "significant investment programme". For 2021, organic growth was 37%. Expects annual revenue of USD450 million and adjusted earnings before interest, tax, depreciation and amortisation of around USD45 million. This would be ahead of revenue consensus of USD383 million and adjusted Ebitda consensus of USD42.9 million. Would represent 70% revenue growth and 47% climb in adjusted Ebitda from 2020.

----------

Pebble Group PLC - Manchester-based technology and services for promotional products industry - Says revenue for 2021 to be around GBP115 million, up from GBP82.4 million in 2020 and beating 2019's GBP107.2 million, which was before onset of pandemic. It expects an adjusted Ebitda of GBP15 million, up from GBP9.8 million in 2020 but down a touch from GBP15.2 million in 2019.

----------

Poolbeg Pharma PLC - London-based clinical stage infectious disease pharmaceutical company - Licenses RNA-based immunotherapy for respiratory virus infections developed at the University of Warwick. "Poolbeg has secured an exclusive licence to this dual antiviral prophylactic and therapeutic candidate, which is at a late-pre-clinical development stage," company says. "The candidate, which will be developed by Poolbeg as POLB 002, was developed at the University of Warwick and derived from twenty years of research with world class virologists, Professor Andrew Easton and Professor Nigel Dimmock."

----------

Midatech Pharma PLC - Cardiff-based drug delivery technology company - Extends research and development pact with Janssen Pharmaceutical NV, owned by Johnson & Johnson. "Under the extended collaboration the company will focus on maximizing drug loading and optimizing in vitro duration of release for this undisclosed Janssen experimental molecule using the company's Q-Sphera technology," Midatech says.

----------

Helium One Global Ltd - London-based exploration & development company - Says remote sensing work at Rukwa, Eyasi and Balangida project areas finds "additional helium anomalies". "Evidence of a robust helium anomaly across the Tai structure where drilling last year encountered numerous helium shows," company says. "Multiple surface anomalies identified within all three basins that require follow up geophysical investigation."

----------

Future Metals NL - Australia-focused platinum group metals explorer - Reports "further high-grade PGM assay results" at Panton project in Australia. "Metallurgical flotation test work is underway on both high-grade and low-grade representative composite samples," Future Metals says. Notes results pending for further 52 drill holes.

----------

88 Energy Ltd - Alaska-focused oil exploration and appraisal company - Says permit to drill Merlin-2 in final stages of review by Bureau of Land Management in Alaska. Affirms project timeline. Company explains: "Permitting and planning for the Merlin-2 well is now largely complete, with the well on track to spud in February 2022. The Merlin-2 permit to drill is in the final stages of review by the BLM and is on schedule to be issued ahead of rig mobilisation."

----------

Ncondezi Energy Ltd - coal-fired power project in Mozambique - Updates on power project in Tete, Mozambique. Says awaiting further clarity on China's position on financing coal projects. Adds China Machinery Engineering Corp "remains committed" to project. Ncondezi is funded to end of first half of 2022, company adds.

----------

Drumz PLC - London-based investment company - Says 25% owned investee Acuity Risk Management Ltd wins several new customers for Stream risk management product. Says major broadcaster with "global reach" adopts Stream, ass does a "multinational German industrial control and automation company".

----------

H&T Group PLC - Surrey, England-based pawnbroker - Expects pretax profit for 2021 to be within range of current market expectations, which stand between GBP9.0 million and GBP10.1 million. "Demand for pledge lending has now fully recovered to pre-pandemic levels, with positive momentum across the customer spectrum and in all geographies. The months of November and December saw particularly strong borrowing demand, with lending volumes in December ahead of expectations and at record levels. Loan-to-value ratios have been maintained. Redemption rates remain stable and above historic norms," H&T says. "Retail sales have continued to remain robust, with consistently strong demand for high quality pre-owned watches and jewellery both online and in H&T's store network."

----------

By Eric Cunha; ericcunha@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
20 Jul 2022 12:04

IN BRIEF: Poolbeg Pharma shares rise as first human trial begins

Poolbeg Pharma PLC - London-based pharmaceutical company - Receives approval to commence its Lipopolysaccharide human clinical trial for POLB 011, a drug that aims to treat severe influenza. The trial will formally start on Friday. It will assess POLB 011 in damping the immune response to lipopolysaccharide, which acts as a surrogate for the hyperinflammatory response associated with severe influenza. Initial results are expected in the final quarter of 2022. Poolbeg says at that point it intends to "rapidly" monetise by out-licensing and/or partnering with pharmaceutical and biotechnology companies for the drug's further development.

Read more
27 Jun 2022 10:47

Poolbeg Pharma AI model of respiratory syncytial virus starts analysis

(Alliance News) - Poolbeg Pharma PLC on Monday said its build and optimisation of an artificial intelligence model of respiratory syncytial virus data is complete.

Read more
27 May 2022 10:43

AIM WINNERS & LOSERS: Premier Miton advances; Advance Energy retreats

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Friday.

Read more
26 May 2022 16:54

IN BRIEF: Poolbeg Pharma shares soar on US patent grants

Poolbeg Pharma PLC - London-based pharmaceutical company - Wins patent grants from the US Patent & Trademark Office for its POLB 001 and POLB 002 molecules. The former is used to treat influenza, while the latter is an RNA-based immunotherapy for respiratory virus infections. "The company is continuing working with its patent advisors to broaden and expand the POLB 001 and POLB 002 patent families," Poolbeg says.

Read more
26 May 2022 10:51

AIM WINNERS & LOSERS: Poolbeg wins patents; RA swings to loss

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Thursday.

Read more
12 May 2022 15:35

TRADING UPDATES: Secure Trust lending up; Eurocell sales climb

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
27 Apr 2022 20:15

IN BRIEF: Poolbeg hails shareholder confidence as lock-up period ends

Poolbeg Pharma PLC - London-based pharmaceutical company - Confirms proposals have been accepted by distribution in specie shareholders seeking to sell a total of GBP366,000 of Poolbeg shares, representing only 3% of the distribution in specie shares. Says 97% of distribution in specie shareholders have decided to remain invested in Poolbeg following the end of the lock-up period.

Read more
14 Apr 2022 21:36

TRADING UPDATES: Polar Capital assets up; Brooks Macdonald funds fall

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and Wednesday and not separately reported by Alliance News:

Read more
14 Apr 2022 14:53

Poolbeg granted European patent for antiviral nose spray

(Sharecast News) - Clinical-stage pharmaceutical company Poolbeg Pharma reported on the strengthening of its intellectual property (IP) for its 'POLB 002' asset on Thursday - a first-in-class, intranasally-administered RNA-based immunotherapy for respiratory virus infections.

Read more
13 Apr 2022 19:46

TRADING UPDATES: McKay backs Workspace offer; IOG fixes Blythe fault

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:

Read more
11 Apr 2022 21:58

TRADING UPDATES: TruFin raises GBP10 million, Afentra preferred bidder

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

Read more
11 Apr 2022 10:57

AIM WINNERS & LOSERS: Mothercare misses payment; Argos licence renewed

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Monday.

Read more
31 Mar 2022 21:07

TRADING UPDATES: SSE's Transmission raises cash; Croda gets UK grant

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

Read more
30 Mar 2022 19:25

IN BRIEF: Poolbeg Pharma starts trading on OTCQB Venture Market

Poolbeg Pharma PLC - London-based pharmaceutical company - Shares start trading on the OTCQB Venture Market in the US.

Read more
28 Mar 2022 15:10

UK shareholder meetings calendar - next 7 days

Tuesday 29 March 
Impax Asset Management Group PLCAGM
Tekmar Group PLCAGM
Wednesday 30 March 
Brunner Investment Trust PLCAGM
Mediazest PLCAGM
Micro Focus International PLCAGM
Parsley Box Group PLCGM re equity raise
Power Metal Resources PLCGM re carried forward losses
Power Metal Resources PLCAGM
Thursday 31 March 
Pressure Technologies PLCAGM
Red Rock Resources PLCAGM
Aukett Swanke Group PLCAGM
Various Eateries PLCAGM
Toople PLCAGM
BiVictriX Therapeutics PLCAGM
CloudCoCo Group PLCAGM
Friday 1 April 
Gfinity PLCGM re fundraising
River & Mercantile Group PLCAGM
Monday 4 April 
Poolbeg Pharma PLCAGM
  
Copyright 2022 Alliance News Limited. All Rights Reserved.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.